A Phase 1/2, Multicentre, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Naldemedine in Paediatric Patients Who Are Receiving or Who Are About to Receive Treatment with Opioids
Latest Information Update: 21 Oct 2024
At a glance
- Drugs Naldemedine (Primary)
- Indications Constipation
- Focus Pharmacokinetics
- Sponsors Shionogi
- 14 Oct 2024 Planned End Date changed from 13 Aug 2024 to 15 Jun 2026.
- 14 Oct 2024 Planned primary completion date changed from 13 Aug 2024 to 15 Jun 2026.
- 18 Sep 2024 This trial is ongoing in Belgium according to European Clinical Trials Database record.